Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, S. | - |
dc.contributor.author | Lee, P. | - |
dc.contributor.author | Han, J. | - |
dc.contributor.author | Kim, S.-N. | - |
dc.contributor.author | Lim, J. | - |
dc.contributor.author | Park, D.-H. | - |
dc.contributor.author | Paik, Tae Jong | - |
dc.contributor.author | Min, Junhong | - |
dc.contributor.author | Park, C.G. | - |
dc.contributor.author | Park, W. | - |
dc.date.accessioned | 2023-06-12T08:41:26Z | - |
dc.date.available | 2023-06-12T08:41:26Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1738-2696 | - |
dc.identifier.issn | 2212-5469 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/66727 | - |
dc.description.abstract | Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming. © 2023, Korean Tissue Engineering and Regenerative Medicine Society. | - |
dc.format.extent | 17 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Tissue Engineering and Regenerative Medicine Society | - |
dc.title | Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s13770-022-00515-8 | - |
dc.identifier.bibliographicCitation | Tissue Engineering and Regenerative Medicine, v.20, no.3, pp 371 - 387 | - |
dc.identifier.kciid | ART002962852 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000943161700001 | - |
dc.identifier.scopusid | 2-s2.0-85149301092 | - |
dc.citation.endPage | 387 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 371 | - |
dc.citation.title | Tissue Engineering and Regenerative Medicine | - |
dc.citation.volume | 20 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Cancer immunotherapy | - |
dc.subject.keywordAuthor | Chimeric antigen receptor (CAR) | - |
dc.subject.keywordAuthor | Genetic engineering | - |
dc.subject.keywordAuthor | Immune cell reprograming | - |
dc.subject.keywordAuthor | Nanoparticle | - |
dc.subject.keywordPlus | NATURAL-KILLER-CELLS | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | MESSENGER-RNA | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | DESIGN | - |
dc.subject.keywordPlus | NANOTECHNOLOGY | - |
dc.subject.keywordPlus | GENERATION | - |
dc.subject.keywordPlus | PRINCIPLES | - |
dc.subject.keywordPlus | BIOLOGY | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalWebOfScienceCategory | Cell & Tissue Engineering | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.